

Technical Data Sheet

RecombiMAb anti-mouse VEGF-A (LALA-PG)



bioxcell.com

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: CP214
Clone: 2G11-2A05-CP214
Isotype: Mouse IgG2a (LALA-PG), κ
Recommended Isotype Control(s): RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer
Mutations: LALA-PG
Immunogen: N-terminal 24 AA sequence of murine VEGF
Reported Applications: ELISA
Western blot
in vivo VEGF-A neutralization
*Reported for the original 2G11-2A05 antibody.
Formulation: PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin: $\leq 0.5\text{EU/mg}$ ($\leq 0.0005\text{EU}/\mu\text{g}$)
Determined by LAL assay
Purity: $\geq 95\%$
Determined by SDS-PAGE
Sterility: $0.2\ \mu\text{m}$ filtration
Production: Purified from mammalian cell supernatant in an animal-free facility
Aggregation: $< 5\%$
Determined by SEC
Molecular Weight: 150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

The 2G11-2A05-CP214 monoclonal antibody is a recombinant, chimeric version of the original 2G11-2A05 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG2a, κ to mouse IgG2a, κ for use in murine models. Additionally, the constant region includes the Fc silencing mutation variant LALA-PG, rendering it unable to bind endogenous murine Fc γ receptors or C1q to induce antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). This allows for pure VEGF-a blockade without Fc γ R or complement mediated effector functions so the biological readout reflects neutralization rather than immune cell depletion or Fc-dependent inflammation. Fc-silent antibodies can also improve in-vitro assays by reducing non-specific signaling and

background. The LALA-PG variant has demonstrated significantly reduced effector function, C1q binding and C3 fixation compared to other common silencing mutations while retaining favorable biophysical and manufacturing properties and preserving FcRn-mediated half-life. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies. Species-matched antibodies result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies. The 2G11-2A05-CP214 monoclonal antibody reacts with mouse VEGF-A (vascular endothelial growth factor A). VEGF-A is a 45 kDa homodimeric, disulfide-linked glycoprotein that plays key roles in angiogenesis, vasculogenesis, and endothelial cell growth. It promotes mitogenesis, chemotaxis, and vascular permeability. Most tumors have a requirement for angiogenesis, and inhibition of VEGF binding to VEGF receptors has been the focus of several tumor therapeutic strategies. The 2G11-2A05 antibody neutralizes the biological activity of VEGF-A.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit [?utm_source=cr9k1b#tab_references](https://bioxcell.com/?utm_source=cr9k1b#tab_references) or scan the QR code below.



Bio X Cell, LLC

<https://bioxcell.com>

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © Bio X Cell, LLC